A team of researchers has designed AI software that can forecast the recurrence of kidney cancer. The researchers, who are all from St. Mary’s Seoul Hospital, were led by Department of Urology Prof. Hong Seung-hoo. The research findings were reported in the “JMIR Medical Informatics” journal.
The proposed algorithm can be used to forecast the probability of kidney recurrence five to 10 years after surgeries have been performed. It can predict this through the use of AI machine learning.
In a press release, the group of researchers stated that they expect their software will be used as the foundation for finding ways to improve a kidney cancer patient’s diagnosis given that the disease doesn’t have an established data platform, either globally or locally.
The researchers used the Korea Renal Cell Carcinoma database to create their AI software. They analyzed data from 6,849 cancer patients on the database using the primary statistical method and obtained 31 variables that influence the recurrence of renal cancer.
After this, they chose 10 variables that considerably impacted actual clinical trials then applied these variables to 8 machine learning algorithm types. This helped them confirm that the best machine learning algorithm for use was the Naïve Bayes algorithm, whose performance they optimized by improving the algorithm’s parameters. They found the forecasted value of recurrence to be 0.79 in a decade after surgery and 0.84 in five years.
Hong stated that the researchers were confident that their algorithm could assist clinicians in managing the diagnosis of patients after renal cancer operations. This benefit is in addition to helping create personalized treatment plans for each patient.
Kidney cancer has become widespread in Korea in the recent past. This cancer type is not easy to detect, as there’s only a 10% to 15% chance that its symptoms, which include abdominal masses, bloody stools and pain in the sides, show in an individual.
The disease’s recurrence after an operation typically appears one to two years after operation. However, there have been reports of its recurrence more than a decade after surgery, which is why a follow-up examination for progression or recurrence after an operation is important. This applies to patients who may not be showing any symptoms, as recurrence may not display any symptoms.
The disease’s recurrence rate is especially high if there’s a risk factor for metastasis such as renal vein invasion or lymph node metastasis, or the cancer size is bigger than 7 cm. It should be noted that metastasis primarily occurs in the liver, bones and lungs.
As cases of cancer increase worldwide, there is a growing interest in plant-based formulations, such as supplements, to promote better health and wellness. Several firms such as Healthy Extracts Inc. (OTCQB: HYEX) are establishing their dominance in this growing plant extracts segment.
NOTE TO INVESTORS: The latest news and updates relating to Healthy Extracts Inc. (OTCQB: HYEX) are available in the company’s newsroom at https://ibn.fm/HYEX
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
